2760250-80-2
2760250-80-2
Chemical Structure
Puxitatug samrotecan
Synonym(s): AZD 8205; P-Sam
- CAS No.: 2760250-80-2
- Formula:N/A
- Molecular Weight:N/A
SMILES: [Puxitatug samrotecan]
Biological Activity: Puxitatug samrotecan (AZD 8205) is an antibody-drug conjugate (ADC) targeting B7-H4, formed by the random conjugation of the Puxitatug (HY-P990059) antibody and AZ14170133 (HY-145399) via interchain cysteine reduction. Puxitatug samrotecan binds to B7-H4 to deliver the payload to B7-H4-expressing cells, inhibits topoisomerase I, and induces cytotoxicity in cancer cells and xenograft models. Puxitatug samrotecan can be used in studies of B7-H4-expressing tumors[1][2][3][4][5][6].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Puxitatug samrotecan | 98.51% | Puxitatug samrotecan (AZD 8205) is an antibody-drug conjugate (ADC) targeting B7-H4, formed by the random conjugation of the Puxitatug (HY-P990059) antibody and AZ14170133 (HY-145399) via interchain cysteine reduction. Puxitatug samrotecan binds to B7-H4 to deliver the payload to B7-H4-expressing cells, inhibits topoisomerase I, and induces cytotoxicity in cancer cells and xenograft models. Puxitatug samrotecan can be used in studies of B7-H4-expressing tumors. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Kinneer K, et al. Design and Preclinical Evaluation of a Novel B7-H4-Directed Antibody-Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305. Clinical cancer research : an official journal of the American Association for Cancer Research. 2023 Mar 14;29(6):1086-1101. [Content Brief]
- [2]. Baird RD, et al. 300MO Puxitatug samrotecan (P‑Sam, AZD8205) in patients (pts) with HR+/HER2‑ breast cancer (BC): A first‑in‑human phase I/IIa dose escalation and expansion study. ESMO Open. 2025 May;10(Suppl 4):104872.
- [3]. Gaillard S, et al. Safety and preliminary efficacy of puxitatug samrotecan (AZD8205) in patients with endometrial cancer: A first‑in‑human phase I/IIa study. Gynecologic Oncology. 2025 Sep;200(Suppl 1):347‑348.
- [4]. Meric‑Bernstam F, et al. 6060 Initial results from a first‑in‑human study of the B7‑H4‑directed antibody‑drug conjugate (ADC) AZD8205 (puxitatug samrotecan) in patients with advanced/metastatic solid tumors. Annals of Oncology. 2024 Sep;35(Suppl 2):S485‑S486.
- [5]. Oh DY, et al. Safety and efficacy of puxitatug samrotecan (Puxi-Sam, AZD8205) in patients with biliary tract cancer (BTC): a first-in-human phase 1/2a study (BLUESTAR) [abstract]. J Clin Oncol. 2026;44(16_suppl):4106.
- [6]. Mileshkin LR, et al. Updated safety and efficacy of puxitatug samrotecan (Puxi‑Sam, AZD8205) in patients (pts) with endometrial cancer (EC) or ovarian cancer (OC): Phase 1/2a BLUESTAR study. Journal of Clinical Oncology. 2026 Jun;44(16_suppl):5515.
